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ETS gene fusions have been characterized in a majority of prostate cancers; however, the key molecular
alterations in ETS-negative cancers are unclear. Here we used an outlier meta-analysis (meta-COPA) to iden-
tify SPINK1 outlier expression exclusively in a subset of ETS rearrangement-negative cancers (10% of total
cases). We validated the mutual exclusivity of SPINK1 expression and ETS fusion status, demonstrated
that SPINK1 outlier expression can be detected noninvasively in urine, and observed that SPINK1 outlier
expression is an independent predictor of biochemical recurrence after resection. We identified the aggres-
sive 22RV1 cell line as aSPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1
attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers.
SIGNIFICANCE
While ETS rearrangements play a role in a majority of prostate cancers, little is known about molecular alterations driving
ETS gene fusion-negative cancers. In this study, we identified SPINK1 outlier expression exclusively in a subset of ETS-neg-
ative cancers. SPINK1 is associated with prostate cancer aggressiveness and can be detected noninvasively in urine. Fur-
thermore, SPINK1 mediates invasion in a prostate cancer cell line with outlier expression. The mechanism of SPINK1 outlier
expression remains to be characterized and is not explained by chromosomal rearrangement, deletion, or amplification.
Thus,SPINK1 is a biomarker specific to a subset of aggressive ETS-negative prostate cancers. Our study also demonstrates
the utility of a meta-outlier strategy to identify cancer subtypes.Cancer Cell 13, 519–528, June 2008 ª2008 Elsevier Inc. 519
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SPINK1 in ETS-Negative Prostate CancerINTRODUCTION
Recently, we developed a bioinformatics approach termed Can-
cer Outlier Profile Analysis (COPA) to nominate candidate onco-
genes from transcriptomic data based on high expression in
a subset of cases (‘‘outlier expression’’) (Tomlins et al., 2005).
When applied to the Oncomine compendium of tumor profiling
studies (http://www.oncomine.org) (Rhodes et al., 2004), COPA
correctly identified several known oncogenes as outliers, such
as ERBB2 in breast cancer and PBX1 in leukemia. In addition,
COPA identified the ETS family members ERG and ETV1 as
high-ranking outliers in multiple prostate cancer profiling studies,
leading to the discovery of recurrent gene fusions involving the 50
untranslated region of the androgen-regulated gene TMPRSS2
with ERG, ETV1, ETV4, or ETV5 in prostate cancer cases that
overexpressed the respective ETS family member (Helgeson
et al., 2008; Tomlins et al., 2005, 2006). Recently, we identified
additional 50 fusion partners in cases with ETS family member
outlier expression (Tomlins et al., 2007a).
ETS gene fusions occur in 40%–80% of prostate-specific
antigen (PSA)-screened prostate cancers, leaving 20%–60% of
prostate cancers in which the key genetic aberration cannot be
ascribed to ETS gene fusions. Additionally, we have determined
that ETS-positive and -negative cancers have distinct transcrip-
tional signatures across profiling studies (Tomlins et al., 2007b),
suggesting that fusion-negative cancers activate unique onco-
genes and downstream targets. Here, we attempted to identify
such candidate oncogenes through their outlier expression in
ETS-negative prostate cancers.
The utility of COPA and other strategies to identify outlier
genes from microarray data was recently demonstrated in multi-
ple myeloma and breast cancer (Annunziata et al., 2007; Naderi
et al., 2007), suggesting that this strategy can be applied across
human cancers to identify relevant subtypes. Here, we refined
our COPA strategy based on observations from our initial appli-
cation of COPA. We observed that correctly identified onco-
genes, including ERG and ETV1, were typically high-ranking out-
liers in multiple data sets (Tomlins et al., 2005). This suggests that
true candidate oncogenes should demonstrate strong outlier
profiles across independent studies and supports the use of
a meta-analysis-based COPA approach.
RESULTS AND DISCUSSION
Thus, in this study, we performed a focused application of COPA
to seven prostate cancer profiling studies (Dhanasekaran et al.,
2001; Glinsky et al., 2004; Lapointe et al., 2004; LaTulippe
et al., 2002; Vanaja et al., 2003; Welsh et al., 2001; Yu et al.,
2004) in the Oncomine database (Rhodes et al., 2004), as
described in the Experimental Procedures, to prioritize candi-
date oncogenes in ETS-negative prostate cancers. Twenty-
nine genes were nominated as outliers in at least three of the
seven data sets (see Table S1 available online), with 11 genes
identified as outliers in at least four of the seven data sets (Table
1). Consistent with our previous application of COPA filtered by
causal cancer genes (Tomlins et al., 2005), both ERG and
ETV1 were high-ranking meta-outliers: ERG ranked as the first
meta-outlier (seven studies) and ETV1 as the fifth meta-outlier
(four studies).520 Cancer Cell 13, 519–528, June 2008 ª2008 Elsevier Inc.To identify candidate oncogenes activated in ETS-negative
prostate cancers, we analyzed the remaining top meta-outliers
for two characteristics: (1) overexpression in prostate cancer
compared to benign prostate tissue and (2) mutually exclusive
overexpression with ERG and ETV1 (as 95% of cancers with
ERG or ETV1 overexpression have detectable ETS fusions
[Tomlins et al., 2005, 2007a]). Specific examples of meta-outliers
that failed one or both criteria are shown in Figure S1 and Table 1.
We identified SPINK1 (serine peptidase inhibitor, Kazal type 1),
the second-ranked meta-outlier, as showing overexpression in
prostate cancer compared to benign prostate tissue and mutu-
ally exclusive overexpression with ERG and ETV1 across multi-
ple studies. SPINK1 was not measured in one of the studies in
the meta-analysis (Lapointe et al., 2004) and ranked in the top
ten in two of the remaining six studies.
The profile of SPINK1 expression and scatter plots with ERG
and ETV1 for two studies (Glinsky et al., 2004; Yu et al., 2004)
where SPINK1 was identified as a top 100 outlier are shown in
Figure 1, with plots from the other four studies in the meta-anal-
ysis (Dhanasekaran et al., 2001; LaTulippe et al., 2002; Vanaja
et al., 2003; Welsh et al., 2001) shown in Figure S2. SPINK1
expression in an additional unpublished prostate cancer profiling
study (NCBI GEO data set GSE8218, where SPINK1 was the
third-ranked outlier at the 90th percentile) and two multicancer
studies profiling prostate cancer (Su et al., 2001 and NCBI GEO
data set GSE2109) is also shown in Figure S2. In total, from
these nine studies, SPINK1 showed outlier expression (see
Experimental Procedures) in only 4 of 136 (2.9%) benign prostate
tissue samples and 56 of 376 (14.9%) clinically localized
prostate cancers (two-sided Fisher’s exact test, p = 9.5E7).
Remarkably, 372 of 376 profiled clinically localized prostate
cancers (98.9%) showed mutually exclusive outlier expression
Table 1. Meta-COPA Analysis of Seven Prostate Cancer Gene







1 ERGa 7 19.3
2 SPINK1a,b 5 29.8
3 GPR116c 5 46
4 ORM1d 4 10
5 ETV1a 4 23
6 MYL2d 4 26.8
7 NEBd 4 27
8 TGM4d 4 30.8
9 NELL2d 4 33.5
10 KRT13d 4 49
11 SLC26A4d 4 63.3
Genes were ranked by the number of studies in which they scored in the
top 100 outliers (ranked by COPA) at any of the three predefined percen-
tile cutoffs (75th, 90th, and 95th). Genes were further ranked by their
average COPA rank in studies in which they ranked in the top 100.
aETS gene.
b Gene showing outlier expression exclusively in prostate cancer and
mutually exclusive outlier expression with ETS genes.
c Gene without mutual exclusivity with ERG or ETV1 outlier expression.
d Gene showing outlier expression in benign prostate tissue.
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SPINK1 in ETS-Negative Prostate Cancerof SPINK1, ERG, and ETV1, as shown in Figure 1, Figure S2, and
Table S2.
To confirm the outlier expression ofSPINK1 exclusively inETS-
negative prostate cancers, we measured SPINK1, ERG, and
ETV1 expression by quantitative PCR (qPCR) in an independent
cohort of 10 benign prostate tissues and 61 prostate cancers
(54 clinically localized and 7 metastatic samples). While ERG,
ETV1, and SPINK1 showed outlier expression in 25 (41%), 4
(6.5%), and 4 (6.5%) of 61 prostate cancers (clinically localized
and metastatic), respectively, no benign prostate tissue samples
demonstrated outlier expression of these genes. Consistent with
the above microarray studies, ERG, ETV1, and SPINK1 showed
outlier expression in distinct cancers (Figure S3).
After demonstrating that SPINK1 outlier expression defines
a subset of ETS rearrangement-negative prostate cancers at
the transcript level, we evaluated the expression of SPINK1 pro-
tein in prostate cancers. By immunohistochemical (IHC) analysis
of tissue microarrays (TMAs), we evaluated SPINK1 expression in
two independent cohorts (University of Michigan [UM] and Swed-
ish Watchful Waiting [SWW]) representing a total of 392 cases of
clinically localized prostate cancers. We have previously evalu-
ated both cohorts for TMPRSS2:ERG fusion status by fluores-
cence in situ hybridization (FISH) (Demichelis et al., 2007; Mehra
et al., 2007). In both cohorts, prostate cancer epithelia exhibited
either strong or no expression of SPINK1, without intermediate
Figure 1. Meta-COPA Identifies SPINK1 as
a Mutually Exclusive Outlier with ERG and
ETV1 in Prostate Cancer
Meta-COPA analysis of seven prostate cancer
gene expression profiling data sets in Oncomine.
The expression of SPINK1 and scatter plots of
ERG versus SPINK1 and ETV1 versus SPINK1
expression are shown from two studies (Glinsky
et al., 2004; Yu et al., 2004) where SPINK1 ranked
as a top-100 COPA outlier.
(A) Expression of SPINK1, in normalized expres-
sion units (non-median centered), for all profiled
samples including benign prostate tissue (blue)
and clinically localized prostate cancer (PCa, red)
as well as Gleason pattern 6, 7, 8, or 9 prostate
cancer (magenta, orange, light blue, and purple,
respectively).
(B and C) Scatter plots for ERG versus SPINK1 (B)
and ETV1 versus SPINK1 (C) for all samples in
both studies. Outlier expression is delineated by
dashed gray lines (see Experimental Procedures).
See Figure S2 for SPINK1 outlier expression in
additional prostate cancer profiling studies.
staining as observed for many prostate
cancer markers. As shown in Figure 2, in
the UM cohort, 10 and 36 of 75 cases
were positive for SPINK1 expression
(13.3%) and TMPRSS2:ERG fusions
(48%), respectively, with all SPINK1-pos-
itive cases being TMPRSS2:ERG-nega-
tive (one-sided Fisher’s exact test, p =
0.0008). In the SWW cohort, 23 and 57
of 312 cases were positive for SPINK1
expression (7.4%) and TMPRSS2:ERG fusions (18.3%), respec-
tively, again with all SPINK1-positive cases being TMPRSS2:
ERG-negative (one-sided Fisher’s exact test, p = 0.008).
Approximately 25%–40% of patients treated by radical pros-
tatectomy for clinically localized prostate cancer will experience
disease recurrence, initially indicated by an increase in the serum
level of PSA (biochemical recurrence) (Han et al., 2001; Hull et al.,
2002). Thus, we next sought to determine whether SPINK1
outlier status was associated with biochemical recurrence after
surgical resection. We identified two data sets from the evalu-
ated cohorts for which we had access to follow-up biochemical
recurrence information and a sufficient number of SPINK1-pos-
itive cases (>5). We first examined the Glinsky et al. (2004) gene
expression data set, which contained tumors from 79 patients
(with 37 recurrences), 10 of which showed outlier mRNA tran-
script expression of SPINK1. These patients had a significantly
higher risk of recurrence than patients without SPINK1 outlier
expression (hazard ratio = 2.65; 95% CI = 1.16–6.07; log rank
p = 0.016) by Kaplan-Meier analysis (Figure 3A). Multivariate
Cox proportional-hazards regression analysis also revealed
that SPINK1 outlier status, independent of Gleason score, lymph
node status, surgical margin status, age, and preoperative PSA,
was a significant predictor of clinical recurrence of prostate
cancer (hazard ratio = 2.5; 95% CI = 1.1–6.0; p = 0.035;
Table S3).Cancer Cell 13, 519–528, June 2008 ª2008 Elsevier Inc. 521
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cases, 28 recurrences) evaluated for SPINK1 status by IHC. By
Kaplan-Meier analysis, SPINK1-positive staining was significantly
associated with biochemical recurrence (hazard ratio = 2.49; 95%
CI = 1.01–6.18;p = 0.04; Figure 3B).Multivariate Coxproportional-
hazards regression analysis again confirmed that SPINK1 status
predicted recurrence independently of other clinical parameters
(Table S3). With an adjusted hazard ratio of 4.1 (95% CI = 1.4–
11.7; p = 0.009), it was the strongest predictor in this model.
As a final validation, we performed IHC for SPINK1 status on
an independent cohort of 817 evaluable prostate cancers (200
recurrences) from the Memorial Sloan-Kettering Cancer Center
(MSKCC). In this MSKCC cohort, with IHC performed indepen-
dently from the UM and SWW cohorts using a different SPINK1
antibody, 297 of the 817 cases (36%) showed positive SPINK1
immunoreactivity in at least one of three triplicate cores. In addi-
tion, staining intensity was more variable than that observed in
the UM and SWW cohorts. As the percentage of cases in this
cohort with SPINK1 staining (36%) was far greater than the other
IHC cohorts (13% and 7%) or the percentage of SPINK1 outlier
samples from DNA microarray and qPCR studies (15% and 7%;
Figure 2. Confirmation of SPINK1 Outlier Expression Exclusively in
ETS-Negative Prostate Cancers
SPINK1 protein expression was evaluated in two cohorts (University of Mich-
igan [UM] and Swedish Watchful Waiting [SWW]) using immunohistochemistry
(IHC) on tissue microarrays previously evaluated for TMPRSS2:ERG status by
fluorescence in situ hybridization (FISH).
(A) Representative SPINK1-positive and -negative cores, along with cells from
the same cores negative and positive for TMPRSS2:ERG rearrangement by
FISH. A TMPRSS2:ERG rearrangement through intrachromosomal deletion
is indicated by loss of one 50 (green) ERG signal.
(B) Contingency tables for SPINK1 expression and TMPRSS2:ERG status and
p values for Fisher’s exact tests for both cohorts.522 Cancer Cell 13, 519–528, June 2008 ª2008 Elsevier Inc.see Table S4), we defined SPINK1-positive cases in the MSKCC
cohort as those with at least one core showing >80% of cells
showing positive SPINK1 immunoreactivity, resulting in 75
SPINK1-positive cases (9%), consistent with the other studies.
By Kaplan-Meier analysis, SPINK1-positive cases in the
MSKCC cohort showed significantly shorter time to biochemical
recurrence (hazard ratio = 2.32; 95% CI = 1.59–3.39; p = 6.96E–
06; Figure 3C). Multivariate Cox proportional-hazards regression
analysis again confirmed thatSPINK1 outlier status, independent
of Gleason score, lymph node status, surgical margin status,
seminal vesicle invasion, extracapsular extension, and preopera-
tive PSA, was a significant predictor of clinical recurrence (hazard
ratio = 2.02; 95% CI = 1.37–2.99; p = 0.0004; Table S3). Clinically,
nomograms are commonly used to predict the likelihood of bio-
chemical recurrence after surgical resection by optimally incor-
porating clinical and pathological parameters. To determine
whether the addition of SPINK1 improves a validated nomogram
for predicting the 7-year postprostatectomy probability of bio-
chemical recurrence (Kattan et al., 1999), we assessed the con-
cordance index (Kattan et al., 2003) (the probability that given
two randomly selected patients, the patient with the worse out-
come is indeed predicted to have a worse outcome) of the
nomogram and the nomogram plus SPINK1 status. The boot-
strap-corrected concordance index was minimally improved in
all three data sets by the addition of SPINK1 status to the nomo-
gram (Glinsky et al., [2004], 0.772 versus 0.762; UM IHC, 0.698
versus 0.676; MSKCC, 0.775 versus 0.765). Thus, while SPINK1
does not dramatically add to the predictive ability of an optimized
multivariate model, we demonstrated by analyzing 971 cancers
from three independent cohorts that SPINK1 outlier status
identifies an aggressive subset of prostate cancers.
We next sought to determine whether outlier expression of
SPINK1 could be detected noninvasively. As increased serum
levels of SPINK1 occur in multiple malignancies (Paju and Sten-
man, 2006; Stenman, 2002), and as 44% of patients with prostate
cancer are reported to have elevated serum levels of SPINK1
(Paju et al., 2007), we sought to establish a more specific assay
to identify patients with tumors showing SPINK1 outlier expres-
sion.We have recently described the detection ofTMPRSS2:ERG
fusion transcripts in the urine of men with prostate cancer (Lax-
man et al., 2006), and this assay allows us to more directly assess
transcripts contributed by prostatic cells. Thus, we assessed
SPINK1 expression from a cohort of 148 urine samples collected
from men with prostate cancer that we have characterized as
TMPRSS2:ERG positive (43) or negative (105). As expected,
SPINK1 expression was higher in TMPRSS2:ERG-negative ver-
sus -positive samples (Mann-Whitney U test, p = 5E–5), and 21
of the 22 samples with the highest SPINK1 expression were
TMPRSS2:ERG negative. Using the same method to identify
SPINK1 outlier samples as described for our tissue qPCR cohort,
1 of the 43 TMPRSS2:ERG-positive samples (2.3%) showed
SPINK1 outlier expression, and 10 of the 105 TMPRSS2:ERG-
negative samples (10%) showed SPINK1 outlier expression (Fig-
ure 4) (Fisher’s exact test, p = 0.12). In addition, compared to urine
collected from 96 men presenting for evaluation of prostate
cancer with negative needle biopsies, SPINK1 expression is a
significant predictor of prostate cancer in both univariate and
multivariate analyses, and no negative samples show SPINK1
outlier expression (Laxman et al., 2008).
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SPINK1 in ETS-Negative Prostate CancerFigure 3. SPINK1 Outlier Expression Identifies an Aggressive Subtype of ETS-Negative Prostate Cancers
Relationship between SPINK1 outlier expression and biochemical recurrence after surgical resection. Kaplan-Meier analyses of SPINK1 outlier expression from
the Glinsky et al. (2004) DNA microarray data set (A) and SPINK1 IHC from the UM (B) and Memorial Sloan-Kettering Cancer Center (MSKCC) (C) cohorts and
biochemical recurrence after surgical resection are shown.Cancer Cell 13, 519–528, June 2008 ª2008 Elsevier Inc. 523SPINK1 encodes a 56 amino acid secreted peptide, also
known as PSTI or TATI. Originally isolated from bovine pancreas
and human pancreatic juice, its normal function is thought to be
the inhibition of serine proteases such as trypsin (Greene et al.,
1976; Haverback et al., 1960; Kazal et al., 1948; Paju and Sten-
man, 2006). SPINK1 levels are strongly elevated during inflam-
mation and pancreatitis (Paju and Stenman, 2006). Like the
pancreas, the prostate gland also secretes a variety of serine
proteases, most notably the kallikrein enzyme PSA, but also
trypsin, the expression of which is increased in prostate cancer
(Bjartell et al., 2005). Thus, SPINK1 outlier expression may
have a role in modulating the activity of cancer-related prote-
ases. Additionally, SPINK1 has been reported to stimulate DNA
synthesis in rat pancreatic cancer cells and human fibroblasts,
suggesting additional roles in oncogenesis (Freeman et al.,
1990; Ogawa et al., 1985). SPINK1 mRNA and protein have
been detected in a variety of benign and cancerous tissues,
and its expression in prostate and prostate cancer has recently
been described (Paju et al., 2007; Paju and Stenman, 2006;
Figure 4. SPINK1Outlier Expression Can BeDetected Noninvasively
in Urine
Noninvasive detection of SPINK1 outlier expression in men with
TMPRSS2:ERG-negative prostate cancers. Total RNA was isolated from the
urine of 148 men with prostate cancer and assessed for TMPRSS2:ERG and
SPINK1 expression by quantitative PCR. Samples above the dashed red line
show SPINK1 outlier expression (see Experimental Procedures).Stenman, 2002). It is notable that SPINK1 is also overexpressed
in other cancers, and elevated serum level is an independent
prognostic sign in many of these (reviewed in Paju et al., 2007;
Paju and Stenman, 2006).
To investigate a functional role for SPINK1 in prostate cancer,
we generated adenoviruses expressing SPINK1 and infected the
benign immortalized prostate epithelial cell line RWPE to gener-
ate RWPE-SPINK1 cells. Overexpression of SPINK1 had no
significant effect on the proliferation or invasion of RWPE cells
(Figures 5A and 5B). As SPINK1 overexpression had no effect
on benign prostate cells, we hypothesized that SPINK1 overex-
pression may occur later in prostate cancer progression in the
presence of coexisting genetic lesions, consistent with its asso-
ciation with aggressive prostate cancer.
Thus, we analyzed a panel of prostate cancer cell lines to iden-
tify an appropriate in vitro model for SPINK1 outlier expression.
We identified marked overexpression of SPINK1 exclusively in
the 22RV1 cell line (Figure 5C), consistent with previous work
reporting high expression in this cell line (Paju et al., 2007). The
aggressive 22RV1 prostate cancer cell line was derived from
a human prostate carcinoma xenograft that was serially propa-
gated in nude mice after castration-induced regression and
relapse of the parental, androgen-dependent CWR22 xenograft
(Sramkoski et al., 1999). Importantly, 22RV1 does not overex-
press ERG or ETV1 (Figure 5C), similar to clinical SPINK1 outlier
cases, supporting its use as a cell line model of SPINK1 outlier
expression. To assess the function of SPINK1 in 22RV1, we uti-
lized siRNA knockdown. WhileSPINK1 knockdown had no effect
on 22RV1 proliferation (Figure 5D), SPINK1 knockdown mark-
edly attenuated the invasiveness of 22RV1 cells through a mod-
ified basement membrane (Figures 5E and 5F). Similar results
were obtained with two additional siRNA duplexes targeting
SPINK1 (Figure S4).
Consistent with the mutually exclusive overexpression ofERG,
ETV1, and SPINK1, siRNA knockdown of ERG or ETV1 in 22RV1
had no effect on invasion, while SPINK1 knockdown had no
effect on the invasiveness of VCaP (TMPRSS2:ERG+, SPINK1)
or LNCaP (ETV1 rearrangement+, SPINK1) (Figures 5G and
5H). Importantly, siRNA knockdown of ERG in VCaP and ETV1
in LNCaP similarly attenuated invasion (Figures 5G and 5H)
Cancer Cell
SPINK1 in ETS-Negative Prostate CancerFigure 5. Knockdown of SPINK1 in 22RV1 Prostate Cancer Cells Attenuates Invasiveness
(A and B) To recapitulate the outlier expression of SPINK1, we generated adenoviruses expressing SPINK1 or LACZ (control). The benign immortalized prostate
cell line RWPE was infected with SPINK1 or LACZ adenovirus as indicated and assayed for proliferation (A) or invasion (B) through a modified basement mem-
brane.
(C) As these results suggest that SPINK1 may require coexisting genetic lesions to function in prostate cancer, we assayed prostate cancer cell lines by quan-
titative PCR for SPINK1 (yellow), ERG (blue), and ETV1 (green) outlier expression.
(D–F) SPINK1mediates invasiveness in 22RV1 cells. To investigate the role ofSPINK1 in the outlier-expressing cell line 22RV1, cells were treated with transfection
reagent alone (untreated) or transfected with nontargeting or siRNA against SPINK1, ETV1, or ERG as indicated. Cells were assayed for proliferation (D) and in-
vasion (E). Photomicrographs of invaded cells treated with the indicated siRNAs are shown in (F).
(G and H) VCaP (TMPRSS2:ERG-positive) (G) and LNCaP (ETV1 rearrangement-positive) (H) prostate cancer cell lines were treated with transfection reagent
alone (untreated) or transfected with nontargeting or siRNA against SPINK1, ETV1, or ERG as indicated and assayed for invasion.
For all proliferation and invasion experiments, means (n = 3) + SEM are shown, and p values < 0.05 are given.without affecting proliferation (Tomlins et al., 2007a, 2008). Addi-
tionally, microarray analysis of 22RV1-siSPINK1 cells revealed
only limited transcriptional effects (76 features overexpressed,
14 features underexpressed; Table S5 and Figure S5), suggest-
ing that SPINK1 knockdown directly affects cellular invasive-
ness. Together, these results support a role for SPINK1 in pros-
tate cancer invasion, consistent with its overexpression in
aggressive prostate cancers.
The outlier expression of SPINK1 in a subset of prostate
cancers suggested that SPINK1 expression may be activated
by a unique molecular event, similar to TMPRSS2:ETS-positive524 Cancer Cell 13, 519–528, June 2008 ª2008 Elsevier Inc.prostate cancers. However, FISH studies using locus/control
and 50/30 split probes demonstrated no evidence of amplification
or gross rearrangements, respectively, in samples with SPINK1
overexpression (data not shown). Additionally, sequencing of
the SPINK1 coding region identified no mutations in samples
with SPINK1 outlier expression (data not shown). Thus, SPINK1
may be activated by increased transcription, possibly through
promoter mutations affecting regulatory elements. Alternatively,
SPINK1 may be activated by a unique upstream genetic event.
However, few genes show consistent correlation with SPINK1
across data sets (Figure S6), suggesting that SPINK1 would be
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SPINK1 in ETS-Negative Prostate Canceran exclusive downstream target. It is also possible that SPINK1
may be downregulated in TMPRSS2:ETS-positive cancers;
however, we would expect high SPINK1 expression in benign
prostatic epithelium, and the in vitro data described above
support a role for SPINK1 overexpression in prostate cancer
progression.
Future studies will be directed at determining the mechanism
by which SPINK1 is overexpressed in TMPRSS2:ETS-negative
prostate cancers and whether determination of SPINK1 in serum
is of diagnostic and prognostic use.
Although conflicting reports of TMPRSS2:ETS fusion status
and aggressiveness have been reported, recent large-cohort
studies have shown that TMPRSS2:ERG fusion-positive pros-
tate cancers harboring an intrachromosomal deletion between
the TMPRSS2 and ERG loci on chromosome 21 are associated
with aggressiveness (Attard et al., 2008; Demichelis et al., 2007;
Lapointe et al., 2007; Mehra et al., 2007; Nam et al., 2007a,
2007b; Perner et al., 2006; Rajput et al., 2007; Wang et al.,
2006; Winnes et al., 2007; Yoshimoto et al., 2006). Supporting
this hypothesis, in a cohort of patients undergoing rapid autopsy
after death from hormone-refractory metastatic prostate cancer,
we found that all TMPRSS2:ERG fusion-positive patients were
deletion positive (R.M. et al., unpublished data). These ‘‘deletion-
positive’’ TMPRSS2:ERG-positive cases, representing 25% of
all prostate cancers, likely account for the association of
TMPRSS2:ERG positivity with aggressiveness. In this report,
we identify SPINK1-positive samples as defining an aggressive
subset of TMPRSS2:ETS-negative prostate cancers (10% of
all prostate cancers). Future studies will be needed to identify
the molecular mechanisms, including response or resistance
to current therapies, that drive the aggressiveness of
TMPRSS2:ERG deletion-positive and SPINK1-positive prostate
cancers.
In conclusion, using a combination of in silico bioinformatics
analysis coupled with independent experimental validation, we
analyzed data on 1800 prostate cancers, demonstrating the
consistent outlier expression of SPINK1 in TMPRSS2:ETS-nega-
tive prostate cancers (Table S4). We provide evidence that
SPINK1 outlier expression defines an aggressive molecular sub-
type of prostate cancer (10% of cases) not attributable to known
gene fusion events. We hypothesize that the molecular lesion or
lesions that initially drive ETS-negative tumors, which are pres-
ently unclear, may predispose to activation ofSPINK1 expression
later in prostate cancer progression. Additionally, SPINK1-posi-
tive tumors may arise from a different prostate progenitor cell
type than ETS-positive tumors, and SPINK1 expression may be
a marker of this cell type. We demonstrate that SPINK1 may be
monitored noninvasively in urine and thus could serve to comple-
ment gene-fusion-based urine testing for prostate cancer. Addi-
tionally, we demonstrate the utility of 22RV1 as a cell line model
for SPINK1 outlier expression. Finally, we extend the utility of
our original COPA approach by using a meta-COPA strategy to
nominate candidate oncogenes in specific cancer types.
EXPERIMENTAL PROCEDURES
Cancer Outlier Profile Analysis and Outlier Analysis
Cancer Outlier Profile Analysis (COPA) analysis was performed on seven pros-
tate cancer gene expression data sets (Dhanasekaran et al., 2001; Glinskyet al., 2004; Lapointe et al., 2004; LaTulippe et al., 2002; Vanaja et al., 2003;
Welsh et al., 2001; Yu et al., 2004) in Oncomine 3.0 (http://www.oncomine.
org) as described previously (Tomlins et al., 2005). (1) For each data set con-
sidering all samples, gene expression values are median centered per gene,
setting each gene’s median expression value to 0. (2) The median absolute
deviation (MAD) is calculated per gene and scaled to 1 by dividing each
gene expression value by its MAD. Of note, median and MAD are used for
transformation as opposed to mean and standard deviation so that outlier ex-
pression values do not unduly influence the distribution estimates and are thus
preserved postnormalization. (3) For each gene in each data set, COPA scores
are computed as the 75th, 90th, and 95th percentile of ascending transformed
gene expression values. Thus, each gene in each data set has three COPA
scores, one at each percentile cutoff, representing the degree of overexpres-
sion in decreasing subsets of cases. (4) In each data set, all genes are rank
ordered by the three COPA scores, generating three rank-ordered lists of genes
per data set. (5) For each data set, we defined outlier genes as those that
ranked in the top 100 COPA scores in any one of the three rank-ordered lists.
(6) To identify ‘‘meta-outlier’’ genes, we ranked genes by the number of data
sets in which the gene was identified as an outlier gene. Genes identified as out-
liers in the same number of studies were further ranked by their average outlier
rank across those studies. This process is summarized in Figure S7. Data sets
can be accessed in Oncomine by searching for ‘‘[author last name]_prostate’’
(e.g., ‘‘Yu_prostate’’).
SPINK1 expression was also interrogated in prostate cancer specimens
from two multicancer profiling studies (Su et al., 2001 and the International
Genomics Consortium’s expO data set GSE2109) and the Yang et al. ‘‘Gene
expression data from prostate cancer samples’’ data set (NCBI GEO data set
GSE8218). The two multicancer studies were not included in the meta-analy-
sis, as prostate cancer samples comprised a minority of the profiled samples,
and GSE8218 was not available at the time the meta-analysis was performed.
Individual samples showing outlier expression in each data set were identi-
fied by a two-step process that recreates the visual process of identifying the
natural ‘‘gap’’ between nonoutlier and outlier sample populations. First, Onco-
mine-generated gene expression values (ERG, ETV1, and SPINK1) for all pros-
tate samples in each data set (non-COPA transformed, excluding metastatic
prostate cancer) were median centered. Next, for each gene, all samples
were rank ordered in ascending order, and the difference between each
rank-ordered sample and the preceding sample was calculated. In each data
set, ERG showed two distributions of expression separated by a natural gap
in expression levels. This visual gap for each data set was quantified after order-
ing the samples as just described and ranged from 0.22 to 1.0 (median 0.63)
normalized expression units. This same method was then applied to define
ETV1 outlier expression, with the natural gap for ETV1 populations ranging
from 0.25 to 2.1 (median 0.48), except for the GSE2109 study, which showed
no ETV1 outlier population. SPINK1 populations showed a similar distribution
in all data sets, with the natural gap ranging from 0.27 to 1.3 (median 0.41).
Hence, formally described, the first sample with a positive median-centered
value and a difference of >0.22 normalized expression units compared to the
preceding sample marked the transition to the outlier population for all genes
in each data set (Figure S8). Specific reporters used and the number ofSPINK1,
ERG, andETV1 outliers for each data set are shown in Table S2. Outlier expres-
sion in quantitative PCR (qPCR) samples (tissue and urine) was determined
similarly, except that normalized expression values for each target gene were
log transformed before median centering and rank ordering. Metastatic pros-
tate cancer samples were also included in the qPCR tissue cohort.
Samples
Tissues used for qPCR were from the radical prostatectomy series at the Uni-
versity of Michigan and from the Rapid Autopsy Program, both of which are
part of the University of Michigan Prostate Cancer Specialized Program of
Research Excellence (SPORE) Tissue Core. For combined fluorescence
in situ hybridization (FISH) and immunohistochemistry (IHC) evaluation, the
University of Michigan (UM) cohort consisted of samples from the radical pros-
tatectomy series. The Swedish Watchful Waiting (SWW) cohort consisted of
samples from a Swedish population-based cohort of men with localized pros-
tate cancer diagnosed incidentally by transurethral resection of the prostate
for symptomatic benign prostatic hyperplasia as described previously (Andren
et al., 2006; Johansson et al., 2004). The Memorial Sloan-Kettering CancerCancer Cell 13, 519–528, June 2008 ª2008 Elsevier Inc. 525
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SPINK1 in ETS-Negative Prostate CancerCenter (MSKCC) cohort consisted of patients with localized or locally ad-
vanced prostate cancer treated by radical prostatectomy at MSKCC between
1985 and 2003. All samples were obtained with institutional review board ap-
proval from the respective institutions (UM, MSKCC, or O¨rebro Medical Center
for the SWW cohort). The prostate cancer cell line 22RV1 was provided by Jill
Macoska (University of Michigan).
Quantitative PCR from Tissue Samples
qPCR was performed using SYBR green dye on an Applied Biosystems 7300
Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) essentially
as described previously (Tomlins et al., 2005, 2006). Briefly, total RNA was iso-
lated from tissues using TRIzol (Invitrogen, Carlsbad, CA, USA). RNA was
quantified using a ND-1000 spectrophotometer (NanoDrop Technologies, Wil-
mington, DE, USA) and 3–5 mg of total RNA was reverse transcribed into cDNA
using SuperScript III (Invitrogen) in the presence of random primers. All qPCR
reactions were performed with Power SYBR Green Master Mix (Applied
Biosystems) and 25 ng of both the forward primer and the reverse primer using
the manufacturer’s recommended thermocycling conditions. For each exper-
iment, threshold levels were set during the exponential phase of the qPCR
reaction using Sequence Detection Software version 1.2.2 (Applied Biosys-
tems). The amount of ERG, ETV1, and SPINK1 relative to the average of the
housekeeping genes GAPDH and HMBS for each sample was determined
using the comparative threshold cycle (Ct) method (according to Applied Bio-
systems User Bulletin #2, http://www3.appliedbiosystems.com/cms/groups/
mcb_support/documents/generaldocuments/cms_040980.pdf). All oligonu-
cleotide primers were synthesized by Integrated DNA Technologies (Coralville,
IA, USA). GAPDH, HMBS, ERG (exon5_6), and ETV1 (exon6_7) primers were
as described previously (Tomlins et al., 2005). Sequences for SPINK1 are
as follows: SPINK1_f, 50-CAAAAATCTGGGCCTTGCTGAGAAC-30; SPINK1_r,
50-AGGCCTCGCGGTGACCTGAT-30. Approximately equal efficiencies of the
primers were confirmed using serial dilutions of pooled prostate cancer
cDNA in order to use the comparative Ct method. All reactions were subjected
to melt-curve analysis.
Immunohistochemistry and Fluorescence In Situ Hybridization
IHC for the UM and SWW cohorts was performed using a mouse monoclonal
antibody against SPINK1 (H00006690-M01; Abnova, Taipei City, Taiwan) on
tissue microarrays (TMAs) containing cores from 75 (UM) and 312 (SWW) evalu-
able cases of localized prostate cancer. Cases with staining in any cancerous
epithelial cells were deemed positive (median 40%, range 1%–90%). Previ-
ously, we have evaluated cases on these tissue microarrays forTMPRSS2:ERG
fusion status by FISH using break-apart ERG assays as described (Demichelis
et al., 2007; Mehra et al., 2007; Tomlins et al., 2005). A one-sided Fisher’s exact
test was used to evaluate the relationship between SPINK1 and fusion status,
as these studies were performed with the prior hypothesis that there was an
inverse correlation between SPINK1 expression and fusion status.
MSKCC Immunohistochemistry
IHC for the MSKCC cohort was performed using an in-house mouse monoclo-
nal antibody against SPINK1 (code 6E8; Osman et al., 1993) on tissue microar-
rays containing triplicate cores from 817 evaluable cases of localized prostate
cancer. The percentage of positive tumor cells in each core was estimated and
assigned values of 0%, 5%, or multiples of 10%. The intensity of the expression
was assigned a value of 0, 1, 2, or 3. Triplicate cores from each specimen were
scored separately, and the presence of tumorous tissue in at least two inter-
pretable cores was required to include a case for analysis. We considered
cases as SPINK1 positive if any of the three cores exhibited >80% of cancerous
cells showing positive SPINK1 immunoreactivity (intensity 1–3).
Outcome Analyses
For Kaplan-Meier analysis of the Glinsky et al. (2004) and UM data sets, bio-
chemical recurrence was defined as a 0.2 ng/ml increase in PSA or recurrence
of disease after prostatectomy, such as development of metastatic cancer, if
biochemical recurrence information was not available. For the MSKCC cohort,
only biochemical recurrence, defined as PSA > 0.2 ng/ml after surgical resec-
tion with a second confirmatory PSA measurement > 0.2 ng/ml, was consid-
ered, as all patients with a clinical failure had previously had a biochemical
recurrence. For outcome analysis from the Glinsky et al. (2004) data set,526 Cancer Cell 13, 519–528, June 2008 ª2008 Elsevier Inc.samples positive for outlier expression of SPINK1 were defined as described
above. For the IHC analysis of the UM and MSKCC cohorts, positive cases
were defined as described above. Kaplan-Meier analysis and multivariate
Cox proportional-hazards regression were then used to examine the associa-
tion of SPINK1 with biochemical PSA recurrence. To predict the probability of
disease recurrence, we used the Kattan 7-year postoperative nomogram
(Kattan et al., 1999), and the concordance index of the nomogram and the
nomogram plus SPINK1 status was evaluated using 1000-times bootstrapping
as described (Kattan et al., 2003).
Urine-Based Detection of SPINK1 Expression
Collection of urine, isolation of RNA, RNA amplification, and qPCR for
TMPRSS2:ERG from men with prostate cancer was performed as described
previously (Laxman et al., 2006, 2008). Briefly, 25 ng of isolated RNA was
amplified using a TransPlex Whole Transcriptome Amplification (WTA) kit (Ru-
bicon Genomics, Ann Arbor, MI, USA) according to the manufacturer’s instruc-
tions. For each qPCR reaction, 10 ng of WTA-amplified cDNA was used as
template. 23 Power SYBR Green Master Mix (Applied Biosystems) and
25 ng of both the forward and reverse primers were used for SPINK1, ERG
(primers as described above), and PSA (Laxman et al., 2006). For all experi-
ments, the same threshold and baseline were set using Sequence Detection
Software version 1.2.2 (Applied Biosystems). All samples with a Ct value
greater than 26 for PSA were excluded to remove samples with insufficient
prostate cell recovery. Samples were considered TMPRSS2:ERG positive if
both ERG and TMPRSS2:ERG assays showed Ct values less than 37. The
amount of SPINK1 relative to PSA was determined for each sample using
the comparative Ct method. Outlier samples were identified as described
above. One-sided Fisher’s exact test and Mann-Whitney U tests were used
to evaluate the relationship between SPINK1 and TMPRSS2:ERG status, as
this study was performed with the prior hypothesis that there was an inverse
correlation between SPINK1 expression and fusion status.
In Vitro Overexpression of SPINK1
cDNA of SPINK1 (NM_003122.2), as present in a clinical prostate cancer spec-
imen overexpressing SPINK1, was amplified by RT-PCR using the following
primers, with the forward primer including a consensus Kozak sequence (start
and stop codons underlined): SPINK1_full-f, 50-ACCACCATGAAGGTAACAG
GCATCTTTCTT-30; SPINK1_full-r, 50-TCAGCAAGGCCCAGATTTTTGA-30.
The cDNA product was TOPO cloned into the Gateway entry vector pCR8/
GW/TOPO (Invitrogen), yielding pCR8-SPINK1. To generate adenoviral con-
structs, pCR8-SPINK1 was recombined with pAD/CMV/V5 (Invitrogen) using
LR Clonase II (Invitrogen). Control pAD/CMV/LACZ clones were obtained
from Invitrogen. Adenoviruses were generated by the University of Michigan
Vector Core. The benign immortalized prostate cell line RWPE was infected
with SPINK1 or LACZ adenoviruses, generating RWPE-SPINK1 and RWPE-
LACZ for transient overexpression.
Proliferation Assay
Proliferation for RWPE-LACZ and RWPE-SPINK1 cells was measured by a
colorimetric assay based on the cleavage of the tetrazolium salt WST-1 by mi-
tochondrial dehydrogenases (cell proliferation reagent WST1; Roche Diagnos-
tics, Mannheim, Germany) at the indicated time points in triplicate. Cell counts
for 22RV1 cells were estimated by trypsinizing cells and analysis by Coulter
counter (Beckman Coulter, Fullerton, CA, USA) at 72 hr in triplicate.
Invasion Assays
For invasion assays, RWPE-SPINK1 and RWPE-LACZ cells (48 hr after infec-
tion with adenoviruses) or 22RV1 cells were used. Equal numbers of the indi-
cated cells were seeded onto the basement membrane matrix (EC matrix;
Chemicon, Temecula, CA, USA) present in the insert of a 24-well culture plate,
with fetal bovine serum added to the lower chamber as a chemoattractant. Af-
ter 48 hr, noninvading cells and EC matrix were removed using a cotton swab.
Invaded cells were stained with crystal violet and photographed. The inserts
were treated with 10% acetic acid, and absorbance was measured at 560 nm.
SPINK1 Knockdown
For siRNA knockdown of SPINK1 in 22RV1 cells, the individual siRNAs com-
posing the Dharmacon SMARTpool against SPINK1 (LQ-019724-00; Chicago)
Cancer Cell
SPINK1 in ETS-Negative Prostate Cancerwere tested for SPINK1 knockdown by qPCR, and the most effective single
siRNA (J-019724-07) was used for further experiments. siCONTROL Non-
Targeting siRNA #1 (D-001210-01) or siRNA against SPINK1 was transfected
into 22RV1 cells using Oligofectamine (Invitrogen). After 24 hr, we carried out
a second identical transfection, and cells were harvested 24 hr later for RNA
isolation, invasion assays, or proliferation assays as described above. Invasion
experiments using two other siRNAs directed against SPINK1 (J-019724-05
and J-019724-06; SPINK1-b and -c, respectively) were also performed
(Figure S4).
Expression Profiling
Expression profiling was performed using the Agilent Whole Human Genome
Oligo Microarray (Santa Clara, CA, USA). Total RNA isolated using TRIzol
was purified using the QIAGEN RNeasy Micro Kit (Valencia, CA, USA). One mi-
crogram of total RNA was converted to cRNA and labeled according to the
manufacturer’s protocol (Agilent). Hybridizations were performed for 16 hr at
65C, and arrays were scanned on an Agilent DNA microarray scanner. Images
were analyzed and data extracted using Agilent Feature Extraction Software
9.1.3.1, with linear and lowess normalization performed for each array. For
22RV1-siSPINK1 hybridizations, the reference was 22RV1 cells infected with
nontargeting siRNA. Duplicate hybridizations were performed with duplicate
dye flips, for a total of four arrays. Over- and underexpressed signatures
were generated by filtering to include only features with significant differential
expression (pValueLogRatio < 0.01) in all hybridizations and Cy5/Cy3 ratios
(LogRatio) greater than or less than 1 (unlogged) in all hybridizations, after
correction for the dye flip.
ACCESSION NUMBERS
The 22RV1 expression profiling data are available at the NCBI GEO (http://
www.ncbi.nlm.nih.gov/geo/) under the accession number GSE11132.
SUPPLEMENTAL DATA
The Supplemental Data include five tables and eight figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/6/519/
DC1/.
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